Gamble A R, Bell J A, Ronan J E, Pearson D, Ellis I O
Department of Histopathology, City Hospital, Nottingham.
BMJ. 1993 Jan 30;306(6873):295-8. doi: 10.1136/bmj.306.6873.295.
To determine whether variations in the expression of tumour related antigens can predict the origin of tumours.
Immunohistological study of tumour marker expression in primary adenocarcinomas and respective metastatic deposits. Antibodies to the following tumour markers were used: polymorphic epithelial mucin (NCRC-11 and SM3), carcinoembryonic antigen, carcinoembryonic antigen with non-specific antigen co-specificity, CA125, CA19.9, prostate specific antigens, and thyroglobulin.
Histopathology department of teaching hospital.
100 pathology sections of metastatic adenocarcinoma and their related primary tumours.
Concordance of reactivity between primary and metastatic tumours. Reactivity profiles of tumour sites.
The correct primary site of origin was predicted in 70% (33/47) of tumours in men and 54% (27/43) tumours in women with antibodies SM3, 288, CA19.9, CA125, and PSA (men only). Specificities ranged from 68% for breast tumour to 98% for prostate tumour.
Use of tumour markers in patients presenting with metastatic adenocarcinoma of unknown origin can help localise the probable primary sites and reduce the need for extensive and expensive imaging techniques.
确定肿瘤相关抗原表达的变化是否能够预测肿瘤的起源。
对原发性腺癌及其相应转移灶中肿瘤标志物表达进行免疫组织学研究。使用了针对以下肿瘤标志物的抗体：多形性上皮黏蛋白（NCRC - 11和SM3）、癌胚抗原、具有非特异性抗原共特异性的癌胚抗原、CA125、CA19.9、前列腺特异性抗原和甲状腺球蛋白。
教学医院病理科。
100份转移性腺癌及其相关原发性肿瘤的病理切片。
原发性肿瘤与转移性肿瘤之间反应性的一致性。肿瘤部位的反应性谱。
使用抗体SM3、288、CA19.9、CA125和PSA（仅用于男性），在70%（33/47）的男性肿瘤和54%（27/43）的女性肿瘤中预测出了正确的原发部位。特异性范围从乳腺癌的68%到前列腺癌的98%。
对于出现不明来源转移性腺癌的患者，使用肿瘤标志物有助于定位可能的原发部位，并减少对广泛且昂贵的成像技术的需求。
